Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS)

Change and percent change from baseline to end of treatment (EOT) in high-sensitivity C-reactive protein (hs-CRP)

Time frame: 2 Weeks

Change and percent change from baseline to EOT in Serum amyloid A (SAA)

Time frame: 2 Weeks

Change and percent change from baseline to EOT in Interleukin (IL)-6

Time frame: 2 Weeks

Change and percent change from baseline to EOT in Key symptom score (KSS)

Time frame: 2 Weeks

Change and percent change from baseline to EOT in Individual symptom score on Daily Health Assessment Form, Second Generation (DHAF2)

Time frame: 2 Weeks

Change and percent change from baseline to EOT in Global assessments of disease activity on DHAF2

Time frame: 2 Weeks

Change and percent change from baseline to EOT in Global CAPS symptom assessment by the Investigator

Time frame: 2 Weeks

Change and percent change from baseline to EOT in Individual CAPS symptom assessment by the Investigator

Time frame: 2 Weeks

Number of adverse events

Time frame: 4 Weeks

JTE-162 post-dose plasma concentrations on Day 1

Time frame: 1 Day

JTE-162 trough plasma concentrations on Days 2, 3 and 4, and at the Week 2 Visit (Day 15±2)

Time frame: Day 2, Day 3, Day 4 and Day 15±2